The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 21, Yifang Biotechnology (Shanghai) Co., Ltd. (abbreviation: Yifang Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, and CITIC Securities is its sole sponsor. The company submitted a listing application to the Hong Kong Stock Exchange on January 1 of this year. According to the prospectus, Yifang Biotech was founded in 2013 and is a biopharmaceutical company focusing on tumors, autoimmune diseases and metabolic diseases. Yifang Biotech has eight candidate products, including two self-developed core products, D-2570 and Terisstrone (D-0502). D-2570 is used to treat autoimmune diseases (including psoriasis, ulcerative colitis (“UC”), systemic lupus erythematosus (“SLE”), psoriatic arthritis (“pSA”), and vitiligo), while terisetran (D-0502) is used to treat ER+HER2-breast cancer. Both core products are currently in phase III clinical trials.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.